In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Excerpts from recent editorials in the United States and abroad: ___ Jan. 26 The Washington Post on Trump's “energy emergency” Oil and gas production in the United States is hitting record highs, ...

"And we're not used to having somebody without a career at stake in the room at a senior level," said Hudson.

It took another year for the FDA to grant interchangeability status to Rezvoglar, meaning it can be substituted at the pharmacy for Lantus, the brand name insulin glargine, without needing a separate ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

That was the case for Lorena Sarmiento, another patient at Erie Health who uses Lantus, an insulin pen. Last fall, after the 340B discount changed, she was quoted $490 at her pharmacy — the ...

If approved as a biosimilar, Semglee will be established as the first direct competitor of Lantus, giving providers an alternative treatment option that they can feel confident in prescribing.

Sanofi-Synthélabo is known for creating meningitis treatment, Menactra, diabetes treatment Lantus, colorectal cancer drug Eloxatin, and lung, prostate and breast cancer drug Taxorete. While this ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...